1. Home
  2. OCGN vs GRAF Comparison

OCGN vs GRAF Comparison

Compare OCGN & GRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCGN
  • GRAF
  • Stock Information
  • Founded
  • OCGN 2013
  • GRAF 2021
  • Country
  • OCGN United States
  • GRAF United States
  • Employees
  • OCGN N/A
  • GRAF N/A
  • Industry
  • OCGN Biotechnology: Biological Products (No Diagnostic Substances)
  • GRAF
  • Sector
  • OCGN Health Care
  • GRAF
  • Exchange
  • OCGN Nasdaq
  • GRAF NYSE
  • Market Cap
  • OCGN 338.2M
  • GRAF 288.1M
  • IPO Year
  • OCGN N/A
  • GRAF 2024
  • Fundamental
  • Price
  • OCGN $0.99
  • GRAF $10.01
  • Analyst Decision
  • OCGN Strong Buy
  • GRAF
  • Analyst Count
  • OCGN 3
  • GRAF 0
  • Target Price
  • OCGN $5.33
  • GRAF N/A
  • AVG Volume (30 Days)
  • OCGN 3.5M
  • GRAF 45.1K
  • Earning Date
  • OCGN 11-08-2024
  • GRAF 01-01-0001
  • Dividend Yield
  • OCGN N/A
  • GRAF N/A
  • EPS Growth
  • OCGN N/A
  • GRAF N/A
  • EPS
  • OCGN N/A
  • GRAF N/A
  • Revenue
  • OCGN $7,263,000.00
  • GRAF N/A
  • Revenue This Year
  • OCGN N/A
  • GRAF N/A
  • Revenue Next Year
  • OCGN N/A
  • GRAF N/A
  • P/E Ratio
  • OCGN N/A
  • GRAF N/A
  • Revenue Growth
  • OCGN 112.62
  • GRAF N/A
  • 52 Week Low
  • OCGN $0.35
  • GRAF $9.03
  • 52 Week High
  • OCGN $2.11
  • GRAF $11.02
  • Technical
  • Relative Strength Index (RSI)
  • OCGN 50.03
  • GRAF N/A
  • Support Level
  • OCGN $0.91
  • GRAF N/A
  • Resistance Level
  • OCGN $0.98
  • GRAF N/A
  • Average True Range (ATR)
  • OCGN 0.07
  • GRAF 0.00
  • MACD
  • OCGN 0.02
  • GRAF 0.00
  • Stochastic Oscillator
  • OCGN 40.08
  • GRAF 0.00

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About GRAF GRAF GLOBAL CORP

Graf Global Corp is a blank check company.

Share on Social Networks: